Vascular protease receptors: Integrating haemostasis and endothelial cell functions

Journal of Pathology

Volumn 190, Issue 3, 2000, Pages 360-372

  Preissner, Klaus T ^a   Nawroth, Peter P ^b   Kanse, Sandip M ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; G PROTEIN COUPLED RECEPTOR; MEMBRANE RECEPTOR; PROTEIN C; PROTEINASE; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN;

BLOOD CLOTTING; BLOOD VESSEL WALL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEMOSTASIS; INFLAMMATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD COAGULATION FACTORS; CELL COMMUNICATION; CELL DIVISION; CELL MOVEMENT; ENDOPEPTIDASES; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE; THROMBOMODULIN; THROMBOPLASTIN;

EID: 0034102401     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200002)190:3<360::AID-PATH574>3.0.CO;2-8     Document Type: Review

References (171)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
2. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
3. Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signalling in vascular cell cell interactions. J Clin Invest 1996; 98: 1699-1702.
4. May AE, Neumann FJ, Preissner KT. The relevance of blood cell-vessel wall adhesive interactions for vascular thrombotic disease. Thromb Haemostas 1999; 82: 962-970.
5. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
6. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood 1994; 83: 3427-3436.
7. Anderson RGW. The caveolae membrane system. Annu Rev Biochem 1998; 67: 199-225.
8. Stan RV, Roberts WG, Predescu D, et al. Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol Biol Cell 1997; 8: 595-605.
9. Schnitzer JE, McIntosh DP, Dvorak AM, Liu J, Oh P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 1995; 269: 1435-1439.
10. Bode W, Brandstetter H, Mather T, Stubbs MT. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, Factor Xa, Factor IXa and protein C. Thromb Haemostas 1997; 78: 501-511.
11. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18: 415-417.
12. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-945.
13. Hajjar KA. Changing concepts in fibrinolysis. Curr Opin Hematol 1995; 2: 345-350.
14. Carmeliet P, Collen D. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis. Trends Cardiovasc Med 1995; 5: 117-122.
15. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998; 91: 255-286.
16. Konigsberg WH, Nemerson Y. Molecular cloning of the cDNA for human tissue factor. Cell 1988; 52: 639-640.
17. Martin DMA, Boys CWG, Ruf W. Tissue factor: molecular recognition and cofactor function. FASEB J 1995; 9: 852-859.
18. Morrissey JH, Neuenschwander PF, Huang Q, McCallum CD, Su B, Johnson AE. Factor VIIa-tissue factor: functional importance of protein membrane interactions. Thromb Haemostas 1997; 78: 112-116.
19. Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 8: 385-390.
20. Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-911.
21. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96: 2311-2315.
22. Holzmuller H, Moll T, Hofer-Warbinek R, Mechtcheriakova D, Binder BR, Hofer E. A transcriptional repressor of the tissue factor gene in endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1804-1811.
23. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffmann T. Evidence for the presence of tissue factor activity on subendothelium. Blood 1989; 73: 968-975.
24. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Med 1996; 2: 209-215.
25. Drake TA, Cheng J, Chang A, Taylor FB. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142: 1458-1470.
26. Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995; 15: 612-621.
27. Houston P, Dickson MC, Ludbrook V, et al. Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thromb Vasc Biol 1999; 19: 281-289.
28. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-623.
29. Bierhaus A, Zhang Y, Deng Y, et al. Mechanism of the tumor necrosis factor-α-mediated induction of endothelial tissue factor. J Biol Chem 1995; 270: 26419-26432.
30. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
31. Tsao BP, Fair DS, Curtiss LK, Edgington TS. Monocytes can be induced by lipopolysaccharide-triggered T lymphocytes to express functional Factor VII/VIIa protease activity. J Exp Med 1984; 159: 1042-1057.
32. Zimmerman GA, Elstad MR, Lorant DE, et al. Platelet-activating factor (PAF): signalling and adhesion in cell cell interactions. Adv Exp Med Biol 1996; 416: 297-304.
33. Fan S-T, Edgington TS. Coupling of the adhesive receptor CD11b/CD18 to functional enhancement of effector macrophage tissue factor response. J Clin Invest 1991; 87: 50-57.
34. Fan ST, Mackman N, Cui MZ, Edgington TS. Integrin regulation of an inflammatory effector gene. Direct induction of the tissue factor promoter by engagement of β1 or α4 integrin chains. J Immunol 1995; 154: 3266-3274.
35. McGilvray ID, Lu Z, Wei AC, Rotstein OD. MAP-kinase dependent induction of monocytic procoagulant activity by β2-integrins. J Surg Res 1998; 80: 272-279.
36. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998; 102: 136-144.
37. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
38. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622.
39. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-188.
40. Brand K, Banka CL, Mackman N, Terkeltaub RA, Fan ST, Curtiss LK. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb 1994; 14: 790-797.
41. Taubman MB, Fallon JT, Scheeler AD, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemostas 1997; 78: 200-204.
42. Bauer KA. Activation of the Factor VII-tissue factor pathway. Thromb Haemostas 1997; 78: 108-111.
43. Mulder AB, Smit JW, Blom NR, Ruiters MH, Halie MR, van der Meer J. Association of smooth muscle cell tissue factor with caveolae. Blood 1996; 88: 1306-1313.
44. Lupu C, Goodwin CA, Westmuckett AD, et al. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2964-2974.
45. Sevinsky JR, Rao LVM, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133: 293-304.
46. Huang Z-F, Higuchi D, Lasky N, Broze GJ. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-951.
47. Zhang Y, Deng Y, Wendt T, et al. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factors-induced tissue factor expression and fibrin deposition in mouse meth-a sarcomas. J Clin Invest 1996; 97: 2213-2224.
48. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 1996; 93: 6258-6263.
49. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-75.
50. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996; 88: 1583-1587.
51. Toomey JR, Kratzer KE, Lasky NM, Broze GJ Jr. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci U S A 1997; 94: 6922-6926.
52. Parry GCN, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 1998; 101: 560-569.
53. Erlich J, Parry GC, Fearns C, et al. Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. Proc Natl Acad Sci U S A 1999; 96: 8138-8143.
54. Clauss M, Grell M, Fangmann C, Fiers W, Scheurich P, Risau W. Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors. FEBS Lett 1996; 390: 334-338.
55. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-1327.
56. Rosen ED, Chan JC, Idusogie E, et al. Mice lacking Factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-294.
57. Chan JCY, Carmeliet P, Moons L, et al. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. J Clin Invest 1999; 103: 475-482.
58. Ruf W, Mueller BM. Tissue factor signalling. Thromb Haemostas 1999; 82: 175-182.
59. Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF-VIIa complex in the cellular initiation of coagulation. Thromb Haemostas 1997; 78: 401-405.
60. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastatsis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemostas 1999; 82: 88-92.
61. Zioncheck TF, Roy S, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase-C-dependent mechanism. J Biol Chem 1992; 267: 3561-3564.
62. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992; 89: 11832-11836.
63. Mueller BM, Ruf W. Requirement for binding of catalytically active Factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 1372-1378.
64. Ott I, Fischer EG, Miyagi Y, Müller BM, Ruf W. A role of tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140: 1241-1253.
65. Randolph GJ, Luther T, Albrecht S, Magdolen V, Muller WA. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood 1998; 92: 4167-4177.
66. Brinkman HJ, Mertens K, Holthuis J, Zwart-Huinink LA, Grijm K, van Mourik JA. The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes. Br J Haematol 1994; 87: 332-342.
67. Stern DM, Knitter G, Kisiel W, Nawroth PP. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol 1987; 66: 227-232.
68. Tijburg P, Ryan J, Stern DM, et al. Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. The role of flow and Factor IX/IXa. J Biol Chem 1991; 266: 12067-12074.
69. Cheung WF, van den Born J, K'hn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for Factor IX. Proc Natl Acad Sci U S A 1996; 93: 11068-11073.
70. Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and Factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283.
71. Stern DM, Nawroth PP, Kisiel W, Handley D, Drillings M, Bartos J. A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin. J Clin Invest 1984; 74: 1910-1921.
72. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell 1990; 61: 657-662.
73. Altieri DC, Etingin OR, Fair DS, et al. Structurally homologous ligand binding of integrin Mac-1 and viral glycoprotein C receptors. Science 1991; 254: 1200-1202.
74. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996; 384: 66-68.
75. Nichols WC, Seligsohn U, Zivelin A, et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998; 93: 61-70.
76. Altieri DC. Coagulation assembly on leukocytes in transmembrane signalling and cell adhesion. Blood 1993; 81: 569-579.
77. Altieri DC. Xa receptor EPR-1. FASEB J 1995; 9: 860-865.
78. Bouchard BA, Catcher CS, Thrash BR, Adida C, Tracy PB. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem 1997; 272: 9244-9251.
79. Gajdusek C, Carbon S, Ross R, Nawroth P, Stern D. Activation of coagulation releases endothelial cell mitogens. J Cell Biol 1986; 103: 419-428.
80. Altieri DC. Proteases and protease receptors in modulation of leukocyte effector functions. J Leukoc Biol 1995; 58: 120-127.
81. Herbert JM, Bono F, Herault JP, et al. Effector protease receptor 1 mediates the mitogenic activity of Factor Xa for vascular smooth muscle cells in vitro and in vivo. J Clin Invest 1998; 101: 993-1000.
82. Cirino G, Cicala C, Bucci M, et al. Factor Xa as an interface between coagulation and inflammation: molecular mimicry of Factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest 1997; 99: 2446-2451.
83. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial vWF is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264: 7768-7771.
84. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994; 144: 975-985.
85. McNamara CA, Sarembock IJ, Gimple LW, Fenton II JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-98.
86. Herbert JM, Dupuy E, Laplace MC, Zini JM, Bar-Shavit R, Tobelem G. Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J 1994; 303: 227-231.
87. Kanthou C, Benzakour O. Cellular effects of thrombin and its signalling pathways. Cell Pharmacol 1995; 2: 293-302.
88. Coughlin SR. Molecular mechanisms of thrombin signalling. Semin Hematol 1994; 31: 270-277.
89. Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemostas 1999; 82: 353-356.
90. Scarborough RM, Naughton MA, Teng W, et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 1992; 267: 13146-13149.
91. Trejo J, Hammes SR, Coughlin SR. Termination of signalling by protease-activated receptor-1 is linked to lysosomal sorting. Proc Natl Acad Sci U S A 1998; 95: 13698-13702.
92. Vu T-KV, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068.
93. Ishihara H, Connolly AJ, Zeng D, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-506.
94. Kahn ML, Zheng Y-W, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-694.
95. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor-4. Proc Natl Acad Sci U S A 1998; 95: 6642-6646.
96. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A 1999; 96: 11023-11027.
97. Connolly AJ, Ishihara H, Kahn ML, Farese RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-519.
98. Sun WY, Witte DP, Degen JL, et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A 1998; 95: 7597-7602.
99. Suh TT, Holmbäck K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-2033.
100. Shivdasani RA, Rosenblatt MF, Zucker FD, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695-704.
101. Even-Ram S, Uziely B. Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med 1998; 4: 909-914.
102. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 1994; 91: 9208-9212.
103. Brass LF, Molino M. Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Thromb Haemostas 1997; 78: 234-241.
104. Alm AK, Norstrom E, Sundelin J, Nystedt S. Stimulation of proteinase activated receptor-2 causes endothelial cells to promote blood coagulation in vitro. Thromb Haemostas 1999; 81: 984-988.
105. Woolkalis MJ, DeMelfi TM, Blanchard N, Hoxie JA, Brass LF. Regulation of thrombin receptors on human umbilical vein endothelial cells. J Biol Chem 1999; 270: 9868-9875.
106. Sambrano GR, Coughlin SR. The carboxyl tail of protease-activated receptor-1 is required for chemotaxis. Correlation of signal termination and directional migration. J Biol Chem 1999; 274: 20178-20184.
107. Molino M, Woolkalis MJ, Reavey-Cantwell J, Pratico D. Andrade-Gordon P. Barnathan ES. Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. J Biol Chem 1997; 272: 11133-11141.
108. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science 1983; 220: 728-731.
109. Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci U S A 1986; 83: 976-980.
110. Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD. Growth promoting effects of esterolytically inactive thrombin. J Cell Biol 1986; 32: 261-272.
111. Bar-Shavit R, Sabbah V, Lampugnani MG, et al. An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion. J Cell Biol 1991; 112: 335-344.
112. Bar-Shavit R, Eskohjido Y, Fenton JW, Esko JD, Vlodavsky I. Thrombin adhesive properties: induction by plasmin and heparan sulfate. J Cell Biol 1993; 123: 1279-1287.
113. Esmon CT, Ding W, Yasuhiro K, et al. The protein C pathway: new insights. Thromb Haemostas 1997; 78: 70-74.
114. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96: 2302-2310.
115. Wen D, Dittmann WA, Ye RD, Deaven LL, Majerus PW. Sadler JE. Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochemistry 1987; 26: 4350-4357.
116. Suzuki K, Kusumoto H. Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6: 1891-1897.
117. Parkinson JF, Koyama T, Bang NU, Preissner KT. Thrombomodulin: an anticoagulant cell surface proteoglycan with physiologically relevant glycosaminoglycan moiety. In Heparin and Related Polysaccharides. Lane DA, Björk I, Lindahl U (eds). Plenum Press: New York, 1992; 177-188.
118. Ye J, Esmon CT, Johnson AE. The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem 1993; 268: 2373-2379.
119. Preissner KT, Koyama T, Tschopp J, Müller-Berghaus G. Domain structure of the endothelial cell receptor thrombomodulin as deduced from modulation of its anticoagulant functions. Evidence for a glycosaminoglycan-dependent secondary binding site for thrombin. J Biol Chem 1990; 265: 4915-4922.
120. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313-330.
121. Koyama T, Parkinson JF, Aoki N, Bang NU, Müller-Berghaus G, Preissner KT. Relationship between post-translational glycosylation and anticoagulant function of secretable recombinant mutants of human thrombomodulin. Br J Haematol 1991; 78: 515-522.
122. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9: 946-955.
123. Sadler JE. Thrombomodulin structure and function. Thromb Haemostas 1997; 78: 392-395.
124. Conway EM, Pollefeyt S, Collen D, Steiner-Mosonyi M. The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis. Blood 1997; 89: 652-661.
125. Braat EAM, Los P, Rijken DC. The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin. Blood Coagul Fibrinol 1998; 9: 419-427.
126. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J. Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemostas 1997; 78: 386-391.
127. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin thrombomodulin complex. J Biol Chem 1995; 270: 25336-25339.
128. Preissner KT. Physiological role of vessel wall related antithrombotic mechanisms: contribution of endogenous and exogenous heparin-like components to the anticoagulant potential of the endothelium. Haemostasis 1990; 20: 30-49.
129. Haley PE, Doyle MF, Mann KG. The activation of bovine protein C by Factor Xa. J Biol Chem 1989; 264: 16303-16310.
130. Wu QY, Tsiang M, Lentz SR, Sadler JE. Ligand specificity of human thrombomodulin equilibrium binding of human thrombin, meizothrombin, and Factor Xa to recombinant thrombomodulin. J Biol Chem 1992; 267: 7083-7088.
131. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A 1995; 92: 850-854.
132. Imada M, Imada S, Iwasaki H, Kume A, Yamaguchi H. Moore EE. Fetomodulin: marker surface protein of fetal development which is modulatable by cyclic AMP. Dev Biol 1987; 122: 483-491.
133. Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M. Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays. Dev Biol 1990; 140: 113-122.
134. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985; 101: 363-371.
135. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-1490.
136. Zhang Y, Weiler-Guettler H, Chen J, et al. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 1998; 101: 1301-1309.
137. Conway EM, Pollefeyt S, Cornelissen J, et al. Structure function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development. Blood 1999; 93: 3442-3450.
138. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-26491.
139. Esmon CT, Xu J, Gu J, et al. Endothelial protein C receptor. Thromb Haemostas 1999; 82: 251-258.
140. Mitro LZ, Taylor FBJ, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 1997; 96: 3633-3640.
141. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997; 100: 411-418.
142. Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102: 1481-1497.
143. Dahlbäck B. Physiological anticoagulation. J Clin Invest 1994; 94: 923-927.
144. Esmon CT. Defects in natural anticoagulant pathways as potential risk factors for myocardial infarction. Circulation 1997; 96: 9-11.
145. Reitsma PH. Protein C deficiency: from gene defects to disease. Thromb Haemostas 1997; 78: 344-350.
146. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
147. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
148. Öhlin AK, Norlund N, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemostas 1997; 78: 396-400.
149. Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemostas 1997; 78: 351-356.
150. Taylor J, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
151. Simmonds RE, Lane DA. Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: comparison with the structure of CDI/major histocompatibility complex α1 and α2 domains. Blood 1999; 94: 632-641.
152. Esmon CT. They're not just for clots anymore: the identification of the blood-clotting inhibitor, protein S, as a ligand for a previously 'orphan' family of receptor tyrosine kinases demonstrates a new role for clotting and anti-clotting proteins in regulating cell proliferation. Curr Biol 1995; 5: 743-746.
153. Benzakour O, Formstone C, Rahman S, et al. Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Biochem J 1995; 308: 481-485.
154. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependenl proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13: 4976-4985.
155. Stitt TN, Conn G, Gore M, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the tyro 3/Axl family of receptor tyrosine kinases. Cell 1995; 80: 661-670.
156. He X, Shen L, Bjartell A, Dahlbäck B. Th gene encoding vitamin K-dependent anticoagulant protein S is expressed in multiple rabbit organs as demonstrated by northern blotting, in situ hybridization, and immunohistochemistry. J Histochem Cytochem 1995; 43: 85-96.
157. Benzakour O, Kanthou C, Kanse SM, Preissner KT. Identification of annexin II as a receptor for the anti-coagulant factor. protein S, in human vascular smooth muscle cells. Thromb Haemostas 1999; 82 (Suppl): 215.
158. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen tissue-plasminogen activator (t-PA). 2. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203.
159. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996; 7: 883-892.
160. Dahlbäck B. Interaction between complement component C4b-binding protein and the vitamin K-dependent protein S. A link between blood coagulation and the complement system. Scand J Clin Lab Invest 1985; 45: 33-41.
161. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994-1004.
162. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101: 1983-1991.
163. Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565-1568.
164. Richardson MA, Gerlitz B, Grinnell BW. Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant. Nature 1992; 360: 261-264.
165. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-1928.
166. Mansuy IM, van der Putten H, Schmid P, Meins M, Botteri FM, Monard D. Variable and multiple expression of protease nexin-1 during mouse organogenesis and nervous system development. Development 1993; 119: 1119-1134.
167. Hoffman M, Pratt CW, Brown RL, Church FC. Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood 1989; 73: 1682-1685.
168. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 1998; 39: 8-33.
169. Degen JL. Haemostatic factors and inflammatory disease. Thromb Haemostas 1999; 82: 858-864.
170. Carmeliet P, Moons L, Dewerchin M, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 1997; 811: 191-206.
171. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-550.